

INTERACTION DIMENSION VERIFICATION

Chancy.AI vs Microsoft Copilot

February 18, 2026 | NMN + Multiple Myeloma Query

Test Query

"What are the statistical outcomes of using NMN supplements during multiple myeloma treatment, and are there any known interactions with current standard-of-care therapies?"

Overall Score — Chancy.AI: 108/120 (90%) vs Copilot: 69/120 (58%). Chancy.AI wins 10 of 12 dimensions, ties 1, loses 1. The dominant differentiator is source quality: Chancy cites 40 peer-reviewed/government sources while Copilot relies primarily on commercial NMN blogs.

Dimension-by-Dimension Scoring

Dimension	Score (C/Co)	Winner
Interaction Dimension Coverage	9/10 / 8/10	Chancy.AI
Source Quantity & Quality	10/10 / 4/10	Chancy.AI
Source Tier Distribution	10/10 / 2/10	Chancy.AI
Clinical Data Specificity	9/10 / 6/10	Chancy.AI
Therapy Enumeration Completeness	9/10 / 8/10	Chancy.AI
Mechanistic Depth (NAD+ Pathway)	8/10 / 7/10	Chancy.AI
Safety Framing & Disclaimers	8/10 / 8/10	Tie
Decision-Support Structure	7/10 / 8/10	Copilot
Follow-Up Suggestions Quality	9/10 / 7/10	Chancy.AI
Source Transparency	10/10 / 3/10	Chancy.AI
Commercial Bias Resistance	10/10 / 2/10	Chancy.AI
Temporal Currency	9/10 / 6/10	Chancy.AI
TOTAL	108 / 69	Chancy.AI

C = Chancy.AI score, Co = Copilot score. Winning score shown in bold color.

Detailed Analysis by Dimension

1. Interaction Dimension Coverage

Chancy.AI: 9/10 | Copilot: 8/10 | Winner: **Chancy.AI**

Chancy names proteasome inhibitors, IMiDs, anti-CD38, BCMA, melphalan, CAR-T, bispecific antibodies (teclistimab), iberdomide. Covers NAD+ pathway interaction with each mechanism class. Copilot covers the same core therapies but omits newer agents (teclistimab, iberdomide) and provides less mechanistic specificity on how NAD+ intersects each drug class.

2. Source Quantity & Quality

Chancy.AI: 10/10 | Copilot: 4/10 | Winner: **Chancy.AI**

Chancy conducted 8 Brave searches across gov, edu, NIH, CDC domains. Cited 40 unique sources including PMC peer-reviewed articles, ClinicalTrials.gov entries, Nature, Frontiers, ScienceDirect, NCCN guidelines, and university cancer centers (UCSF, UCSD, Columbia). Copilot cited 8 links, all from commercial health blogs (biologyinsights.com, healthspanx.org, scienceinsights.org, thepeptidereport.com, omre.co, drgalen.org). Only 1 Copilot source was Tier 1 (NCCN).

3. Source Tier Distribution

Chancy.AI: 10/10 | Copilot: 2/10 | Winner: **Chancy.AI**

Chancy: ~85% Tier 1 (gov/academic/peer-reviewed), ~10% Tier 2 (medical journalism), ~5% Tier 3 (commercial). Copilot: ~12% Tier 1 (NCCN only), ~0% Tier 2, ~88% Tier 3 (commercial supplement blogs). This is a critical quality gap — Copilot's response is overwhelmingly sourced from websites selling or promoting NMN.

4. Clinical Data Specificity

Chancy.AI: 9/10 | Copilot: 6/10 | Winner: **Chancy.AI**

Chancy cites specific trial data: p-values (all $p \leq 0.001$ for NAD+ increases), dosage groups (300/600/900 mg), SF-36 health scores, mutagenicity testing results, and specific clinical trial IDs (NCT04823260, NCT07144527). Copilot states correct conclusions but provides no specific p-values, trial IDs, or dosage data.

5. Therapy Enumeration Completeness

Chancy.AI: 9/10 | Copilot: 8/10 | Winner: **Chancy.AI**

Both engines correctly enumerate standard MM therapies: proteasome inhibitors (bortezomib, carfilzomib), IMiDs (lenalidomide, pomalidomide), anti-CD38 (daratumumab, isatuximab), BCMA, and transplant. Chancy adds teclistimab (bispecific), iberdomide (FDA NDA accepted), and GDA-201 NK cell therapy context. Copilot includes GDA-201 but not newer agents.

6. Mechanistic Depth (NAD+ Pathway)

Chancy.AI: 8/10 | Copilot: 7/10 | Winner: **Chancy.AI**

Both correctly identify the core tension: NMN raises NAD+ which fuels both healthy and malignant cells. Chancy adds Washington University research on muscle glucose metabolism, systematic review data on physical performance, and arterial stiffness RCT data. Copilot correctly identifies ferroptosis mechanism in lung adenocarcinoma and melanoma proliferation but doesn't cite the underlying studies.

7. Safety Framing & Disclaimers

Chancy.AI: 8/10 | Copilot: 8/10 | Winner: **Tie**

Both engines provide responsible framing: 'absence of evidence $\neq$ evidence of safety,' recommend oncology team consultation, and correctly state this would be experimental. Both include appropriate legal disclaimers. Copilot's tone is slightly warmer; Chancy's is more authoritative.

8. Decision-Support Structure

Chancy.AI: 7/10 | Copilot: 8/10 | Winner: **Copilot**

Copilot's numbered bottom-line summary (5 points) is slightly more scannable and decision-ready. Chancy provides the same 5 bottom-line points but embeds them in longer prose sections. Both offer follow-up topic suggestions. Copilot's formatting is marginally better for quick clinical decision-making.

9. Follow-Up Suggestions Quality

Chancy.AI: 9/10 | Copilot: 7/10 | Winner: **Chancy.AI**

Chancy offers 4 specific, research-worthy follow-up topics: proteasome inhibitor + NAD⁺ interaction studies, MM treatment protocols for supplement requests, vitamin D evidence in MM, and NAD⁺ metabolism in hematological malignancies. Copilot offers 4 follow-ups but they're more generic (NAD⁺ metabolism intersections, NMN vs NR vs NAM).

10. Source Transparency

Chancy.AI: 10/10 | Copilot: 3/10 | Winner: **Chancy.AI**

Chancy provides complete source transparency: all 8 search queries shown verbatim, all 40 source URLs listed with full titles, organized by search. User can verify every claim. Copilot shows 8 reference links at the bottom with minimal attribution in-text (just domain names like 'biologyinsights.com'). No search query transparency.

11. Commercial Bias Resistance

Chancy.AI: 10/10 | Copilot: 2/10 | Winner: **Chancy.AI**

Chancy's sources are overwhelmingly independent: PMC, Nature, ClinicalTrials.gov, NCCN, university cancer centers. Zero supplement vendor sites. Copilot's primary sources are commercial NMN-related blogs (biologyinsights.com cited 5+ times, healthspanx.org, drgalen.org) — sites with financial interest in promoting NMN positively. This is a fundamental reliability concern.

12. Temporal Currency

Chancy.AI: 9/10 | Copilot: 6/10 | Winner: **Chancy.AI**

Chancy surfaces 2025-2026 publications: NCCN Guidelines Version 5.2026, Frontiers meta-analysis 2025, FDA NDA acceptance for iberdomide, UCSF/UCSD 2026 clinical trials. Copilot's sources lack clear dates; the commercial blogs don't indicate publication dates and may contain outdated information.

Critical Finding: Copilot's Commercial Bias Problem

The most significant finding in this comparison is not about content completeness — both engines reach similar clinical conclusions. The critical finding is about **source reliability and commercial bias**.

Copilot's response cites biologyinsights.com as its primary source (referenced 5+ times). This is a commercial blog in the NMN/longevity supplement space. Other Copilot sources include healthspanx.org, scienceinsights.org, thepeptidereport.com, omre.co, and drgalen.org — all commercial health content sites, several with direct financial interest in NMN supplementation.

When a cancer patient asks whether a supplement interacts with their chemotherapy, the sources matter as much as the conclusions. Copilot's answer may be factually reasonable, but it is built on a foundation of commercial content rather than peer-reviewed oncology research. Chancy.AI's answer is built on PMC, Nature, ClinicalTrials.gov, NCCN guidelines, and university cancer centers — sources designed for clinical decision-making.

This is exactly the commercial bias detection that Chancy.AI's architecture is designed to prevent.

Interaction Dimension Verification Result

STATUS: PASSED

Therapy / Interaction	Chancy	Copilot
Proteasome inhibitors (bortezomib, carfilzomib)	Yes	Yes
IMiDs (lenalidomide, pomalidomide)	Yes	Yes
Anti-CD38 (daratumumab, isatuximab)	Yes	Yes
BCMA-targeted therapies	Yes	Yes
High-dose melphalan + transplant	Yes	Yes
CAR-T cell therapy (idecabtagene vicleucel)	Yes	No
Bispecific antibodies (teclistimab)	Yes	No
Iberdomide (next-gen IMiD, FDA NDA 2025)	Yes	No
GDA-201 NK cell therapy (Phase I)	Yes	Yes
NAD+ pathway mechanistic interaction	Yes	Yes
Ferroptosis mechanism	No	Yes

Chancy.AI identified 3 therapies that Copilot missed (CAR-T with specific agent name, teclistimab bispecific, iberdomide). Copilot identified ferroptosis mechanism that Chancy.AI did not surface. Net advantage: Chancy.AI.